Pemphigoid of pregnancy (PG) is a rare autoimmune bullous dermatosis, affecting 1 in 20000 to 50000 pregnant women. PG is linked to anti-BP180 autoantibodies whose synthesis follows a breakdown in mother-fetal immunological tolerance. Bullae formation results from a complex mechanism involving TH2 lymphocytes, cytokines and polynuclear cells. PG manifests itself as a pruritic erythematopapular rash of varying extent, progressing to the inconstant but suggestive appearance of vesicles and bullae. The disease progresses to gradual recovery after delivery, sometimes after a post-partum flare-up. Recurrence during subsequent pregnancies is frequent. Relapses can also be triggered by estrogen-progestogen contraception. Diagnosis is confirmed by direct immunofluorescence, which shows C3 +/- IgG deposits along the basement membrane. The BP180-NC16A ELISA technique is highly sensitive for the detection of circulating antibodies. Fetal prognosis is good, but early onset in the 1st or 2nd trimester of pregnancy of pregnancy and the presence of bullae are risk factors for prematurity or hypotrophy. Very rarely, the newborn may present transient bullae. Several publications show that very strong dermocorticoids are effective and can be used as first-line treatment for moderate PG. We report the case of a patient admitted to a maternity hospital emergency department, with a pregnancy of 37 weeks' gestation and a non-reassuring fetal condition presenting as pemphigoid of pregnancy (PG).
Read full abstract